Latest Ramelteon Stories
MORRISTOWN, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S.
US drug labels often omit key information about a medicineâ€™s effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine.
SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif.
Takeda Pharmaceutical Company has announced that its wholly owned subsidiary, Takeda Global R&D Centre, has requested a re-examination of the opinion given by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
By Wade, Alan G Ford, Ian; Crawford, Gordon; McMah
DEERFIELD, Ill., Jan. 19 /PRNewswire/ -- Takeda Global Research & Development Center, Inc. announced that Mehmood Khan, M.D., has been named president, reporting to Dr. Masaomi Miyamoto, general manager, pharmaceutical development division, Takeda Pharmaceutical Company Limited.
TOKYO (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd, said on Monday it is on track to release a sleeping pill as early as September in the United States and may extend its use to treat Alzheimer's disease and other illnesses.
The investigational drug ramelteon reduced the time it took for people with chronic insomnia to fall asleep and also increased their total sleep time, according to the results of a Phase III study sponsored by the drug's maker, Takeda Pharmaceuticals.
Ramelteon, a novel investigational compound under review with the FDA for the treatment of insomnia, reduced the time it took to fall asleep and increased total sleep time in adults with chronic insomnia, according to results from a Phase 3 study presented this week at the 19th Annual Meeting of the Associated Professional Sleep Societies (APSS). Results of the study also showed no evidence of rebound insomnia, next-day impairments or withdrawal effects due to discontinuation.